Meeting
2013 ASCO Annual Meeting
Clinical impact of febrile neutropenia (FN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer.
Authors
Erika Paige Hamilton
Duke Cancer Institute, Durham, NC
Erika Paige Hamilton , Donna L. Topping , Jeffrey M. Peppercorn , P. Kelly Marcom , Gretchen Genevieve Kimmick , Erin Duff , Constance T. Cirrincione , Kimberly L. Blackwell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1076)
DOI
10.1200/jco.2013.31.15_suppl.1076
Abstract #
1076
Poster Bd #
23C
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Prophylactic ciprofloxacin to prevent febrile neutropenia in adjuvant breast cancer patients receiving docetaxel (nonanthracycline) regimens.
First Author: Meena Okera
Poster
2021 ASCO Quality Care Symposium
Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).
First Author: Jaime Shaw
Poster
2011 ASCO Annual Meeting
Incidence of febrile neutropenia with docetaxel plus cyclophosphamide in a university-based breast oncology clinic.
First Author: A. Soni
Poster
2022 ASCO Annual Meeting
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer.
First Author: Danilo Giffoni M. M. Mata